Information Provided By: 
Fly News Breaks for December 10, 2018
IRWD
Dec 10, 2018 | 07:12 EDT
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Ironwood Pharmaceuticals to $11.50 and reiterates a Sell rating on the shares. The company's "poor" recent financial performance is unlikely to improve in the near-term, Selvaraju tells investors in a research note. He expects Linzess pricing decreases and challenges to uptake will continue.
News For IRWD From the Last 2 Days
There are no results for your query IRWD
